Sugi Predict

Sugi Predict / Compounds / SCHEMBL14480692

SCHEMBL14480692

SCHEMBL14480692

Cc1c(F)ccc2cc(C(C)Nc3ncnc4cccnc34)c(N3CCN(C(=O)C(C)(C)C)CC3)nc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.38
▸ CYP3A5 P20815 3/20 0.38
▸ PIK3CD O00329 4/20 0.37
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ SOS1 Q07889 1/20 0.36
▸ PIK3R2 O00459 1/20 0.36
▸ SMO Q99835 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ IDE P14735 1/20 0.33
▸ CD274 Q9NZQ7 1/20 0.33
▸ KRAS P01116 1/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ AKT2 P31751 1/20 0.33
▸ AKT3 Q9Y243 1/20 0.33
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14480691 1.00 CYP3A4 (0.38) CYP3A4CYP3A5PIK3CDTP53MAPT
SCHEMBL14480929 0.92 PIK3CD (0.39) PIK3CDSOS1PIK3R2CD274KRAS
SCHEMBL14480930 0.92 PIK3CD (0.39) PIK3CDSOS1PIK3R2CD274KRAS
SCHEMBL15900051 0.91 PIK3CD (0.38) PIK3CDSOS1PIK3R2DYRK1ACD274
SCHEMBL14481337 0.91 PIK3CD (0.38) PIK3CDSOS1PIK3R2DYRK1ACD274
SCHEMBL14480909 0.89 PIK3CD (0.37) PIK3CDMAPTPIK3R2MEN1KMT2A
SCHEMBL14480910 0.89 PIK3CD (0.37) PIK3CDMAPTPIK3R2MEN1KMT2A
SCHEMBL14481197 0.89 SOS1 (0.40) CYP3A4CYP3A5PIK3CDMAPTSOS1
SCHEMBL15899989 0.88 PIK3CD (0.39) CYP3A4CYP3A5PIK3CDTP53MAPT
SCHEMBL15899853 0.87 PIK3CD (0.39) PIK3CDSOS1PIK3R2KMT2ACD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2499129-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-07-30 — — EP claimed
US-8653105-B2 Quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2014-02-18 — — US claimed
US-20130012517-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2013-01-10 — — US claimed
EP-2499129-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-07-30 — — EP disclosed
US-8653105-B2 Quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2014-02-18 — — US disclosed
US-20130012517-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2013-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012517-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors PDXK, MAP2K2, PDPK1 CYP3A4 1196/4885CYP3A5 1381/4885PIK3CD 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.